EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs

Charles Dharmani iD, Oluwatosin Fofah iD, Pingping Qu iD, Zoe Jiang iD, Jingjian Wang iD, Li Li iD, Yijing Tao iD, Lin Song iD

Journal of Health Economics and Outcomes Research · 11.06.2026 · 13 (1)

DOI: 10.36469/001c.161191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Health Economics and Outcomes Research, online erschienen am 11.06.2026. Verfasst von Charles Dharmani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology, Clinical Safety and Pharmacovigilance Daiichi Sankyo, Inc. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of non-Hodgkin lymphomas associated with aggressive clinical course and suboptimal outcomes. PTCL accounts for a higher proportion of non-Hodgkin lymphoma cases in Japan compared with Western countries; however, real-world evidence on treatment patterns, healthcare resource utilization (HRU), and costs in Japan is limited.

Objectives

To describe real-world patient characteristics, treatment patterns, HRU, and costs among patients with PTCL in Japan.

Methods

This retrospective observational study used administrative claims data from the Medical Data Vision database in Japan. Adult patients diagnosed with PTCL between September 2012 and August 2022 were identified. Patients were categorized as receiving nonsystemic therapy or systemic therapy and stratified by lines of therapy. Patient demographics, comorbidities, treatment regimens, time on treatment, HRU, and healthcare costs, measured per patient per month, were analyzed descriptively.

Results

Among 910 patients identified, 71.3% received systemic treatment and 28.7% received nonsystemic therapy, most receiving corticosteroids only. Mean age at diagnosis was 69.8 years; 70% of patients were at least 65 years old. Key comorbidities included peptic ulcer disease, congestive heart failure, and diabetes. PTCL–not otherwise specified and angioimmunoblastic T-cell lymphoma accounted for over 75% of subtypes. First-line therapy was mainly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens; later lines were more heterogeneous and of shorter duration. Mogamulizumab and brentuximab vedotin were used in 4.16% and 10.48% of patients, respectively. Stem cell transplantation was infrequent (6.3%). Median per patient per month PTCL-related total healthcare cost was $9712; median drug ($7056.9) and hospitalization costs ($5177.7) were the main contributors.

Discussion

These findings demonstrate substantial clinical and economic burden among PTCL patients in Japan. Treatment heterogeneity and short duration in later lines of therapy highlight ongoing therapeutic challenges.

Conclusions

High economic burden of PTCL treatment underscores the need for more effective, tolerable, and less costly therapeutic strategies for treating PTCL patients in Japan.

Schlagwörter

Stichwörter der Autor:innen

Medical Data Visionhealthcare resource utilizationline of therapyperipheral T-cell lymphomasystemic therapytreatment coststreatment patterns

Autor:innen und Institutionen

  • Epidemiology, Clinical Safety and Pharmacovigilance Daiichi Sankyo, Inc.
  • Data and Statistical Sciences Centre for RWE Daiichi Sankyo, Inc.
  • Data and Statistical Sciences Centre for Data Engineering Daiichi Sankyo, Inc.
  • Data and Statistical Sciences Centre for Data Engineering DeltaMed Solutions, Inc.
  • Data Intelligence Department Daiichi Sankyo Co., Ltd.

ORCID-Profile: Charles Dharmani, Oluwatosin Fofah, Pingping Qu, Zoe Jiang, Jingjian Wang, Li Li, Yijing Tao, Lin Song

Zitieren

APA

Dharmani, C., Fofah, O., Qu, P., Jiang, Z., Wang, J., Li, L., Tao, Y., & Song, L. (2026). Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs. Journal of Health Economics and Outcomes Research, 13(1). https://doi.org/10.36469/001c.161191

Vancouver

Dharmani C, Fofah O, Qu P, Jiang Z, Wang J, Li L, et al. Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs. Journal of Health Economics and Outcomes Research. 2026;13(1). doi:10.36469/001c.161191

BibTeX
@article{Dharmani2026,
  author = {Dharmani, Charles and Fofah, Oluwatosin and Qu, Pingping and Jiang, Zoe and Wang, Jingjian and Li, Li and Tao, Yijing and Song, Lin},
  title = {Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs},
  journal = {Journal of Health Economics and Outcomes Research},
  year = {2026},
  volume = {13},
  number = {1},
  doi = {10.36469/001c.161191}
}
Kostenlos starten →